Kristin Brooks, Contract Pharma10.20.20
The research and development (R&D) journey is inherently a long, complex and costly one. Drug developers large and small are partnering with Contract Research Organizations (CROs) early in the development process to help overcome critical challenges and achieve greater efficiencies across the drug development continuum.
In addition to reducing drug development timelines and costs, there are several pharma and biopharma trends contributing to increased outsourcing of R&D activities. Among them, increasingly complex small molecules and biologics requiring extensive ground work, highly specific drug technologies, and expertise.
Dr. David Shoemaker of Rho discusses R&D trends and challenges, efforts to streamline drug development, and the greatest motivators for outsourcing in today’s market. –KB
Contract Pharma: What are the pharma/biopharma R&D trends impacting CROs and services?
David Shoemaker: The bottom line is that any trends that
FREE SUBSCRIPTION
Continue reading this story and get 24/7 access to Contract Pharma for FREE
FREE SUBSCRIPTION
